Johns Hopkins University School of Medicine, United States.
Johns Hopkins University School of Medicine, United States.
J Subst Abuse Treat. 2018 Feb;85:38-44. doi: 10.1016/j.jsat.2017.04.012. Epub 2017 Apr 20.
Extended-release naltrexone (XR-NTX) blocks the effects of opioids for 4weeks; however, starting treatment can be challenging because it requires 7 to 10days of abstinence from all opioids. In the present study we identified patient and treatment characteristics that were associated with successful induction onto XR-NTX.
144 unemployed heroin-dependent adults who had recently undergone opioid detoxification completed self-report measures and behavioral tasks before starting an outpatient XR-NTX induction procedure. Employment-based reinforcement was used to promote opioid abstinence and adherence to oral naltrexone during the induction. Participants were invited to attend a therapeutic workplace where they earned wages for completing jobs skills training. Participants who had used opioids recently were initially invited to attend the workplace for a 7-day washout period. Then those participants were required to provide opioid-negative urine samples and then take scheduled doses of oral naltrexone to work and earn wages. Participants who had not recently used opioids could begin oral naltrexone immediately. After stabilization on oral naltrexone, participants were eligible to receive XR-NTX and were randomized into one of four treatment groups, two of which were offered XR-NTX. Binary and multiple logistic regressions were used to identify characteristics at intake that were associated with successfully completing the XR-NTX induction.
58.3% of participants completed the XR-NTX induction. Those who could begin oral naltrexone immediately were more likely to complete the induction than those who could not (79.5% vs. 25.0%). Of 15 characteristics, 2 were independently associated with XR-NTX induction success: legal status and recent opioid detoxification type. Participants who were not on parole or probation (vs. on parole or probation) were more likely to complete the induction (OR [95% CI]=2.5 [1.1-5.7], p=0.034), as were those who had come from a longer-term detoxification program (≥21days) (vs. a shorter-term [<21days]) (OR [95% CI]=7.0 [3.0-16.6], p<0.001).
Our analyses suggest that individuals recently leaving longer-term opioid detoxification programs are more likely to complete XR-NTX induction. Individuals on parole or probation are less likely to complete XR-NTX induction and may need additional supports or modifications to induction procedures to be successful.
延长释放型纳曲酮(XR-NTX)可阻断阿片类药物的作用长达 4 周;然而,开始治疗可能具有挑战性,因为它需要 7 至 10 天的时间完全戒除所有阿片类药物。在本研究中,我们确定了与成功诱导 XR-NTX 相关的患者和治疗特征。
144 名最近接受过阿片类药物脱毒治疗的失业海洛因依赖成年人在开始门诊 XR-NTX 诱导程序前完成了自我报告的测量和行为任务。就业强化被用来促进阿片类药物的戒除和口服纳曲酮在诱导期间的依从性。邀请参与者参加一个治疗性工作场所,在那里他们完成工作技能培训即可获得工资。最近使用过阿片类药物的参与者最初被邀请参加为期 7 天的洗脱期。然后,要求这些参与者提供阿片类药物阴性的尿液样本,然后服用预定剂量的口服纳曲酮去工作并赚取工资。最近未使用过阿片类药物的参与者可以立即开始服用口服纳曲酮。在口服纳曲酮稳定后,参与者有资格接受 XR-NTX 治疗,并被随机分为四个治疗组中的一组,其中两组接受 XR-NTX 治疗。二项和多项逻辑回归用于确定与成功完成 XR-NTX 诱导相关的摄入特征。
58.3%的参与者完成了 XR-NTX 诱导。那些可以立即开始口服纳曲酮的人比那些不能的人更有可能完成诱导(79.5%比 25.0%)。在 15 个特征中,有 2 个与 XR-NTX 诱导成功独立相关:法律地位和最近的阿片类药物脱毒类型。未被假释或缓刑(假释或缓刑)的参与者更有可能完成诱导(OR [95%CI]=2.5 [1.1-5.7],p=0.034),来自较长时间脱毒治疗方案(≥21 天)(与较短时间脱毒治疗方案(<21 天)相比(OR [95%CI]=7.0 [3.0-16.6],p<0.001)。
我们的分析表明,最近离开较长时间阿片类药物脱毒治疗方案的个体更有可能完成 XR-NTX 诱导。被假释或缓刑的个体不太可能完成 XR-NTX 诱导,并且可能需要额外的支持或对诱导程序进行修改才能成功。